Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Vorinostat × Dermatologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1 Dermatologic 1

Conditions

Sezary Syndrome 1 Lymphoma, T-Cell, Cutaneous 1

Interventions

pembrolizumab 5 Nivolumab 3 cemiplimab 2 Vemurafenib 2 Ipilimumab 2 trametinib 1 relatlimab 1 mogamulizumab 1 lifileucel 1 larotrectinib 1 entrectinib 1 encorafenib 1 dabrafenib 1 cobimetinib 1 binimetinib 1 atezolizumab 1 Vorinostat 1 Melphalan 1 Dacarbazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01728805 2024-04-25

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

Kyowa Kirin Co., Ltd.

Phase 3 Completed

372 enrolled 14 charts 1 FDA

DermatologicLymphoid

Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon ⚡